T1	Participants 51 72	mild asthma patients:
T2	Participants 495 535	mite monosensitive, mild asthma patients
T3	Participants 603 621	26 asthma patients
T4	Participants 907 980	patients were challenged with methacholine (Mth) (until FEV1 fell by 40%)
T5	Participants 2074 2094	mild asthma patients
T6	Participants 285 306	mite-allergic asthma.
